Recently, T cell immunoglobulin and ITIM domain (TIGIT) was found to be co-expressed with PD-1 on tumor-infiltrating lymphocytes (TILs)11, and the combination of PD-L1/PD-1 blockade with anti-TIGIT showed superior ORR and OS than PD-L1/PD-1 single agent in PD-L1 positive (tumor proportion score [TPS] ≥ 1%) cancer patients12. Here, TIGIT is linked to cancer.